(Q50885033)

24 March 2018

title

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. (English)

1 reference

24 March 2018

1 reference

Axel Hoos

1

1 reference

24 March 2018

publication date

11 March 2016

1 reference

24 March 2018

Nature Reviews Drug Discovery

published in

1 reference

24 March 2018

volume

15

1 reference

24 March 2018

issue

4

1 reference

24 March 2018

page(s)

235-247

1 reference

24 March 2018

https://scigraph.springernature.com/pub.10.1038/nrd.2015.35

exact match

0 references

cites work

Inflammation and cancer: back to Virchow?

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

II. Contribution to the Knowledge of Sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

A new member of the immunoglobulin superfamily--CTLA-4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

CTLA-4 can function as a negative regulator of T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

PD-1 and its ligands in tolerance and immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cancer immunotherapy comes of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immune checkpoint blockade: a common denominator approach to cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

A clinical development paradigm for cancer vaccines and related biologics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Phase I/II study of ipilimumab for patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

A methodological framework to enhance the clinical success of cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Improved endpoints for cancer immunotherapy trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Management of immune-related adverse events and kinetics of response with ipilimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Ipilimumab and its toxicities: a multidisciplinary approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The immuno-oncology framework: Enabling a new era of cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Breakthrough of the year 2013. Cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Pembrolizumab: first global approval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Chimeric antigen receptor T cells for sustained remissions in leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab in previously untreated melanoma without BRAF mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Pembrolizumab versus Ipilimumab in Advanced Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Designing tomorrow's vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

NKG2D Receptor and Its Ligands in Host Defense

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cytokines in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The chemokine superfamily revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Adoptive immunotherapy for cancer: harnessing the T cell response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Therapeutic vaccines for cancer: an overview of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

31 March 2020

Bispecific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Tumor-antigen-binding bispecific antibodies for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Big opportunities for small molecules in immuno-oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Going viral with cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

TLR agonists: our best frenemy in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Oncology meets immunology: the cancer-immunity cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The cancer vaccine roller coaster

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Signatures of mutational processes in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

A vaccine targeting mutant IDH1 induces antitumour immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The regulatory landscape for actively personalized cancer immunotherapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Harmonization of immune biomarker assays for clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Guidelines for the automated evaluation of Elispot assays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Improved overall survival in melanoma with combined dabrafenib and trametinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immunogenic cell death in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Combining immunotherapy and targeted therapies in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Hepatotoxicity with combination of vemurafenib and ipilimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immunotherapy: The path to win the war on cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Evolution of end points for cancer immunotherapy trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Do we need a different set of response assessment criteria for tumor immunotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.35

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26965203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26965203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26965203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD.2015.35

1 reference

24 March 2018

PubMed ID

26965203

1 reference

24 March 2018